Biopharma SHAKTI to anchor India's biologics push

A ₹10,000-crore, five-year scheme to build a home-grown ecosystem for biologics and biosimilars and turn India into a global biopharma hub.

What happened

• The Department of Pharmaceuticals informed Parliament that the Government has announced Biopharma SHAKTI, a dedicated scheme for the biologics segment of the pharmaceutical industry.
• The scheme carries an outlay of ₹10,000 crore spread over five years.
• Its stated objective is to build a globally competitive domestic ecosystem for biologics and biosimilars so that advanced therapies become affordable across the country.
• The wider ambition is to let India emerge as a global biopharma manufacturing and innovation hub, rather than remain a buyer of imported biologic medicines.
• The information was placed before the Lok Sabha as a written reply by the Minister of State in the Ministry of Chemicals and Fertilizers.
• The reply specifically noted that affordable healthcare benefits would reach the entire country, with Andhra Pradesh named among the States covered.

Background & context

To read Biopharma SHAKTI correctly, an aspirant needs to separate two halves of the modern pharmaceutical world. Small-molecule drugs are chemically synthesised, have a precisely known structure, and are easy to copy exactly once a patent lapses — the copy is called a generic. Biologics, by contrast, are large, complex molecules — monoclonal antibodies, therapeutic proteins, vaccines, cell and gene therapies, insulin and the like — manufactured inside living cells. Because a living system can never be reproduced atom-for-atom, a copy of an off-patent biologic is not an identical generic but a biosimilar: a product highly similar to the reference biologic, with no clinically meaningful difference in safety or efficacy, but requiring its own analytical and clinical comparison before approval. This single distinction — generic versus biosimilar — is the conceptual spine of the scheme and a frequent point of confusion that examiners exploit.

India earned the title of the "pharmacy of the world" largely on the strength of generics: it supplies a very large share of the world's generic medicines and vaccine doses by volume, built on cheap, high-quality chemical synthesis. That model, however, sits almost entirely in the small-molecule space. Biologics are where the global pharmaceutical industry's value and future growth are concentrated, and they are exactly where India has historically been weakest — dependent on imports for many high-value therapies and on imported cell lines, media, bioreactors and other inputs. Biopharma SHAKTI is the Department of Pharmaceuticals' answer to that gap: a deliberate move up the value chain from copying simple chemistry toward manufacturing and innovating in complex biology.

The scheme does not arrive in a vacuum. It joins a family of industrial-policy instruments the same Department already runs for the sector. The two best-known siblings are the Production Linked Incentive (PLI) Scheme for Pharmaceuticals (approved 2021, with an outlay in the order of ₹15,000 crore) and the earlier PLI Scheme for Bulk Drugs / Key Starting Materials, Drug Intermediates and Active Pharmaceutical Ingredients (approved 2020), which was designed to cut India's dependence on single-source imports of the basic chemical building blocks of medicines. Alongside these sit the affordability-focused Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which runs the Jan Aushadhi Kendra network selling unbranded generics far below branded prices, and the Bulk Drug Parks and Medical Device Parks schemes that build shared manufacturing infrastructure. Biopharma SHAKTI is the newest member of this set and the first squarely aimed at the biologics frontier rather than at chemistry or at retail affordability.

It is worth fixing how Biopharma SHAKTI differs from its closest sibling, the PLI Scheme for Pharmaceuticals, because the two are easy to conflate. The PLI scheme works by paying eligible firms an incentive calculated as a percentage of their incremental sales of notified products over a base year — a back-ended reward for scaling up output of high-value formulations, complex generics, patented drugs and in-vitro diagnostics. By the Department's own figures placed before Parliament on the same day, the pharmaceuticals PLI had already pulled in cumulative investment far above its target and generated very large cumulative sales and exports, while the separate bulk-drugs PLI was rebuilding domestic capacity for active pharmaceutical ingredients and their feedstocks to reduce single-source import risk. Biopharma SHAKTI, by contrast, is described as an ecosystem scheme: rather than simply rewarding incremental sales of an already-defined product list, it is meant to build the underlying capability — manufacturing, inputs and innovation — for biologics and biosimilars, a segment the older PLI schemes did not specifically target. One scheme deepens what India already makes; the new scheme opens a frontier India has barely entered.

A note on the name itself: the scheme is presented as "Biopharma SHAKTI," with "biopharma" pointing to the biopharmaceutical (biologics) segment and "SHAKTI" used in the familiar sense of strength or empowerment for the sector. Aspirants should resist the temptation to over-decode the acronym into a specific full form unless an official notification spells one out; what is established and examinable is the segment it serves, the outlay, the period and the administering Department. This caution matters because question-setters often test whether a candidate has internalised the substance of a scheme rather than memorised a possibly-misremembered expansion.

For Prelims

• Name & meaning: Biopharma SHAKTI — a scheme to strengthen India's biopharmaceutical sector, specifically biologics and biosimilars.
• Outlay & period: ₹10,000 crore, over five years.
• Nodal body: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers (Government of India).
• Core objective: a globally competitive domestic ecosystem for biologics and biosimilars, supporting affordable healthcare nationwide.
• Strategic goal: position India as a global biopharma manufacturing and innovation hub.
• Segment served: biologics (made in living cells) and biosimilars — not chemically synthesised small-molecule generics.
• Announced via: a written reply in the Lok Sabha by the Ministry of Chemicals and Fertilizers, dated 20 March 2026.
• Scheme family: the Department of Pharmaceuticals' policy set also includes PLI for Pharmaceuticals (2021), PLI for Bulk Drugs (2020), Bulk Drug Parks, Medical Device Parks and PMBJP (Jan Aushadhi).

Why it matters

The problem the scheme addresses is structural. The diseases now driving health spending — many cancers, autoimmune and inflammatory conditions, diabetes and rare disorders — are increasingly treated with biologics rather than with simple chemical pills. These therapies are expensive, and where India lacks domestic manufacturing it must import them at prices many patients cannot afford. A strong biosimilars industry is the single most powerful lever for bringing those prices down: once a reference biologic loses exclusivity, competing biosimilars can cut costs sharply, exactly as generics did for small molecules. By funding domestic capacity in this segment, Biopharma SHAKTI aims to convert India's generics advantage — scale, low-cost manufacturing, regulatory experience — into the harder, higher-value biologics space.

There is also a self-reliance dimension. Building biologics depends on inputs — specialised cell lines, growth media, single-use bioreactors, chromatography resins and skilled bioprocess talent — that India still largely imports. An ecosystem scheme, as opposed to a narrow product subsidy, is meant to deepen these supporting layers so that the country is not merely assembling biologics from imported components but can innovate and supply across the chain. Success would strengthen India's position in global health supply chains, support exports of affordable biosimilars to other developing countries, and reduce vulnerability to external shocks of the kind the world saw during recent global health emergencies, when access to advanced biologic products was sharply unequal.

Finally, the scheme carries an innovation message. India's pharmaceutical strength has rested on copying after patents expire; biologics reward firms that can develop novel molecules and master complex bioprocessing. By framing the goal as an "innovation hub" and not only a "manufacturing hub", the Government signals an intent to push domestic firms and research institutions further up the discovery ladder — a move with implications for jobs, high-skill employment and India's standing in cutting-edge life sciences.

For Mains

Source